Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -2.56%30 3-Year EBITDA Growth Rate is 11.70% as of Dec. 2025, which is 49% below its 10-year median of 22.75. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,135 Biotechnology companies, Island Pharmaceuticals ranks worse than 54.36% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Island Pharmaceuticals was 33.80% per year. The lowest was 11.70% per year. And the median was 22.75% per year.
Island Pharmaceuticals (ASX:ILA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Island Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
ASX:ILA vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
Island Pharmaceuticals 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.70% mean?
Island Pharmaceuticals (ASX:ILA) has a 3-Year EBITDA Growth Rate of 11.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Island Pharmaceuticals and its competitors. This is 49% below median its historical median of 22.75. Over the past decade, Island Pharmaceuticals' 3-Year EBITDA Growth Rate has ranged from 11.70 to 33.80. According to the industry distribution chart, Island Pharmaceuticals ranks #617 out of 1135 companies in the Biotechnology industry, placing it in the top 54.4%.
Is Island Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Island Pharmaceuticals' current 3-Year EBITDA Growth Rate of 11.70% is 49% below median its 10-year median of 22.75. Over the past 10 years, this metric has ranged from a low of 11.70 to a high of 33.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Island Pharmaceuticals' value of 11.70% is 21.5% below this industry median. Based on the distribution chart, Island Pharmaceuticals ranks #617 out of 1135 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #617 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Island Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Island Pharmaceuticals' value of 11.70% is 21.5% below this benchmark. Historically, Island Pharmaceuticals' own 3-Year EBITDA Growth Rate has ranged from 11.70 to 33.80 over the past decade. While the company's 10-year median is 22.75 vs. the industry median of 14.90, Island Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Island Pharmaceuticals's current 3-Year EBITDA Growth Rate of 11.70% is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current 3-Year EBITDA Growth Rate is 11.70%, which is 49% below median its own 10-year median of 22.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current 3-Year EBITDA Growth Rate of 11.70%. The current 3-Year EBITDA Growth Rate is 11.70%, which is 49% below median its 10-year median of 22.75 and 21.5% below the Biotechnology industry median of 14.90. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current 3-Year EBITDA Growth Rate is 11.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score
Get the complete analysis for ASX:ILA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
